111 K Street NE
Washington, DC 20002
- Toll Free 1.888.564.6273
- Local 202.783.3870
While the larger debate over liberals' proposed hostile government takeover of America's medical system continues to rage, an opportunity was recently missed to inject some competition in one important area: the life-saving biologic drug market.
The Senate HELP committee passed legislation last week that would prevent generic companies from entering the market to compete with brand providers. These "biogenerics" would provide downward pressure on prices for drugs like Insulin and Avastin (a colon cancer medicine), but not if Congress continues to allow roadblocks to competition.
Click here for a good analysis on the issue from James K. Glassman.